REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract, offering a different mechanism of action from antibiotics.
The post Recursion Advances AI-Based <i>C. Diff</i> Candidate to Phase II appeared first on GEN -…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
SALT LAKE CITY, Utah, March 18, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today […]
SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ — In the heart of Utah’s Wasatch Front, longtime local physician Megan J. Engelen, DO, FACP, is proud to open a new practice model in partnership with MDVIP […]
Top-rated orthopedic clinic adds three new physicians to treat its youngest patients PARK CITY, Utah, Jan. 16, 2024 /PRNewswire/ — The Orthopedic Partners (TOP), a leading orthopedic care provider based in Utah, announced the expansion […]
Copyright © 2026 Biotech Networks
